Besancon Cedex

• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung … Ended recruitment
  2024-511185-37-00 6 2020-11-03 Completely resected stage I or IIA non-squamous non-small cell lung ca
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast … Ended recruitment
  2024-514733-38-00 5 2020-11-03 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Ended recruitment
  2023-506515-18-00 5 2020-10-23 Primary Progressive Multiple Sclerosis (PPMS)
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in … Ended recruitment
  2024-518506-41-00 9 2020-10-05 metastatic castrate resistant prostate cancer
• A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C … Ended recruitment
  2024-517536-22-00 7 2020-09-22 Unresectable or metastatic cutaneous squamous cell carcinoma
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP … Ended recruitment
  2023-504998-20-00 5 2020-09-18 Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended recruitment
  2024-512704-20-00 4 2020-06-22 Unresectable and/or metastatic soft-tissue sarcoma after failure of at
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in … Ended recruitment
  2024-518069-89-00 4 2020-02-03 Patients with solid cancers
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou … Ended recruitment
  2023-509049-11-00 5 2020-01-01 FIGO stage III ovarian cancer who are eligible for primary cytoreducti
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended recruitment
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and … Ended recruitment
  2024-510626-89-00 5 2019-11-18 Non-Alcoholic Steatohepatitis (NASH)
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su … Ended recruitment
  2024-514088-25-00 5 2019-10-07 Multiple Myeloma
• Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi … Ended recruitment
  2024-515946-17-00 5 2019-07-22 Non Small Cell Lung Cancer
• A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f … Ended recruitment
  2024-514705-62-00 5 2019-07-08 Recurrent rectal cancer after local excision
• APIS Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Ended recruitment
  2024-514348-95-00 5 2019-06-24 Intrahepatic non-cirrhotic portal hypertension
• Avelumab Program Rollover Study Ended recruitment
  2024-514274-46-00 5 2019-06-21 Solid Tumors
• A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended recruitment
  2023-508264-29-00 5 2019-06-11 Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer

Showing 265–288 of 383 trials